24 completed, 7 unknown, 2 terminated, 1 active not recruiting. 36 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Completed 24, Unknown 7, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Encephalitis, Arbovirus: new trials by email Literature Review of Encephalitis, Arbovirus trials Research Report on Encephalitis, Arbovirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients Plasma - West Nile Fever | Phase 2 | Recruiting | Gili Regev-Yochay MD | 37 | 2025-07-30 | 2025-08-26 |
| A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine MVA-BN-WEV, Placebo - Encephalitis | Phase 2 | Active not recruiting | Bavarian Nordic | 411 | 2025-03-10 | 2025-10-01 |
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 161 | 2025-02-24 | 2026-09-11 |
| Early Interferon-beta Treatment for West-Nile Virus Infection Rebif 44 MCG Per 0.5 ML Prefilled Syringe, Saline - West Nile Virus, West Nile Fever Encephalitis | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 100 | 2024-07-14 | 2024-07-23 |
| An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Stamaril, Imojev, Ixiaro - Infectious Disease, Yellow Fever | Phase 2 | Unknown | Singapore General Hospital | 70 | 2022-09-28 | 2023-04-12 |
| Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1 - Venezuelan Equine Encephalomyelitis | Phase 2 | Not yet recruiting | U.S. Army Medical Research and Development Command | 500 | 2021-06-01 | 2021-02-16 |
| Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age JEVAX, JECEVAX - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 220 | 2017-06-02 | 2018-09-17 |
| Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine Western Equine Encephalitis (WEE) Vaccine - Western Equine Encephalitis | Phase 2 | Unknown | U.S. Army Medical Research and Development Command | 500 | 2015-12-15 | 2021-02-11 |
| Safety and Immunogenicity of JECEVAX in Young Children JEVAX, JECEVAX-1, JECEVAX-0.8 - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 200 | 2015-04-01 | 2016-06-28 |
| New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 250 | 2015-01-01 | 2021-02-10 |
| Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients TBE virus vaccine - Tick Borne Encephalitis | Phase 2 | Completed | Medical University of Vienna | 34 | 2014-07-01 | 2022-02-03 |
| The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans Japanese Encephalitis vaccine, Yellow Fever vaccine - Yellow Fever, Encephalitis, Japanese | Phase 2 | Completed | Singapore General Hospital | 84 | 2013-10-01 | 2016-04-20 |
| Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 200 | 2011-09-01 | 2015-11-18 |
| Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) FSME-IMMUN 0.5ml Baxter - Tick-Borne Encephalitis, Encephalitis, Tick-Borne | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 69 | 2009-09-25 | 2018-07-05 |
| Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)] - Japanese Encephalitis | Phase 2 | Completed | University of Liverpool | 22 | 2009-05-01 | 2013-05-21 |
| Treatment of West Nile Virus With MGAWN1 MGAWN1, Placebo - normal saline - West Nile Neuroinvasive Disease, West Nile Virus Infection | Phase 2 | Terminated | MacroGenics | 13 | 2009-05-01 | 2022-02-10 |
| Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults ChimeriVax-WN02 vaccine, Placebo - West Nile Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 479 | 2008-10-01 | 2015-04-03 |
| Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine Inactivated, Dried, TSI-GSD 104, EEE - Eastern Equine Encephalitis | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 138 | 2008-06-03 | 2019-09-24 |
| Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 - Eastern Equine Encephalitis | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 138 | 2008-06-03 | 2020-03-17 |
| Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83 VEE C-84 - Venezuelan Equine Encephalomyelitis | Phase 2 | Unknown | U.S. Army Medical Research and Development Command | 500 | 2008-03-01 | 2021-02-11 |
Showing 20 of 36. Sign in to see all of them.
Encephalitis, Japanese (14) · Encephalitis, Tick-Borne (10) · Encephalitis (6) · West Nile Fever (5) · Encephalomyelitis, Venezuelan Equine (3) · Yellow Fever (3) · Encephalomyelitis, Eastern Equine (2) · Virus Diseases (2) · Alphavirus Infections (1) · Communicable Diseases (1) · Encephalomyelitis, Equine (1) · Encephalomyelitis, Western Equine (1) · Hepatitis A (1) · Meningitis (1) · Nervous System Diseases (1)
Arbovirus Infections (36) · Brain Diseases (36) · Central Nervous System Diseases (36) · Central Nervous System Infections (36) · Central Nervous System Viral Diseases (36) · Encephalitis, Viral (36) · Infections (36) · Infectious Encephalitis (36) · Neuroinflammatory Diseases (36) · RNA Virus Infections (36) · Vector Borne Diseases (36) · Nervous System Diseases (35) · Virus Diseases (34) · Encephalitis (30)
Vaccines (4) · Desiccation (3) · Japanese Encephalitis Vaccines (2) · Saline Solution (2) · FSME-IMMUN vaccine (1) · Hepatitis A Vaccines (1) · Immunoglobulins, Intravenous (1) · Interferon beta-1a (1) · Ribavirin (1) · Sodium Chloride (1) · Yellow Fever Vaccine (1)
U.S. Army Medical Research and Development Command (6) · Pfizer (5) · Sanofi (5) · Sanofi Pasteur, a Sanofi Company (3) · National Institute of Hygiene and Epidemiology, Vietnam (2) · Singapore General Hospital (2) · Sormland County Council, Sweden (2) · Bavarian Nordic (1) · Elisabethinen Hospital (1) · Gili Regev-Yochay MD (1) · Indian Council of Medical Research (1) · MacroGenics (1) · Medical University of Vienna (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis (1)
United States (11) · Austria (5) · Australia (4) · Germany (4) · Finland (2) · India (2) · Israel (2) · Singapore (2) · Sweden (2) · Thailand (2) · Vietnam (2) · Czechia (1) · Nepal (1) · New Zealand (1)
Anthony Cardile, DO (2) · Robert Rivard, MD (2) · Thiem D Vu, MD., PhD. (2) · Ulrich Behre, MD (2) · Ajit Rayamajhi, MBBS, MD (1) · Anand Dubey, M.D (1) · Anthony P Cardile, DO, MAJ (1) · Atul Shanker, Dr. (1) · Bakul B. Javadekar, M.D. (1) · Carlos A. Fierro, MD (1) · Christina Forstner, MD (1) · Gili Regev-Yochay, MD (1)
PMID 15714427, PMID 19143532, PMID 20856164, PMID 20864814, PMID 21148499, PMID 21150279, PMID 25872531, PMID 25886645, PMID 27686833, PMID 27815383, PMID 32728481, PMID 33763778, PMID 33899755, PMID 34452033, PMID 35101266, PMID 36780676, PMID 36969244, PMID 39794472, PMID 5063895